Pacira BioSciences (PCRX) EBT (2010 - 2026)

Pacira BioSciences' EBT history runs 17 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• In Q1 2026, EBT fell 42.59% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $13.2 million (up 119.35% YoY), while the FY2025 annual figure was $16.9 million, up 126.74% from the prior year.
• EBT was $5.0 million for Q1 2026 at Pacira BioSciences, up from $571000.0 in the prior quarter.
• In the past five years, EBT ranged from a high of $37.9 million in Q2 2023 to a low of -$138.9 million in Q3 2024.
• Historically, EBT has averaged $2.0 million across 5 years, with a median of $8.7 million in 2025.
• The sharpest annual moves came in 2023 and 2024: EBT surged 702.37% in 2023, then sank 936.43% in 2024.
• A 5-year view of EBT shows it stood at -$18.1 million in 2022, then soared by 286.63% to $33.7 million in 2023, then declined by 24.3% to $25.5 million in 2024, then sank by 97.76% to $571000.0 in 2025, then jumped by 775.31% to $5.0 million in 2026.
• The last three EBT figures came in at $5.0 million (Q1 2026), $571000.0 (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.